Below you will find news and press releases from industry, government, and academia regarding product developments and medical/scientific research news.
Urinary tract infections are one of the indignities many women face as they age. One reason why is because their bladder walls can be invaded by several species of bacteria, a new study finds. Urinary tract infections, or UTIs, are among the most common type of bacterial infections in women, accounting for nearly 25% of all infections. UTI recurrence rates can range from 16%-36% in younger women to 55% in postmenopausal women. In the new study, researchers at University of Texas Southwestern (UTSW) in Dallas analyzed bacteria in bladder biopsies from 14 postmenopausal women with recurrent UTI. The investigators found that, in these patients, several species of bacteria can get inside the bladder’s surface area. Read more.
Source: HealthDay News, May 20, 2019
Domtar Corporation today announced that its Personal Care Division, a leading manufacturer in the disposable incontinence product category for over 35 years, launched their most absorbent and highest performing product line in the Attends® family. The new Attends® Premier product line of briefs, underwear and a premium underpad, has launched to the North American Healthcare market both in-store and online. Read more.
Source: Business Wire, May 20, 2019
If urinary incontinence is affecting your life, please help The Simon Foundation for Continence understand your challenges and give your input to help design a new program we are creating. The study focus groups are 90-minutes long and will take place in June 2019. Current locations are: Evanston, Chicago and Forest Park, Illinois.Continue reading
Today, the American Urological Association (AUA), a leading global urology association, and the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU), released a new clinical guideline on the treatment of urinary incontinence after prostate treatment (IPT). IPT is one of the few urologic conditions that is iatrongenic, and therefore predictable, and often preventable. A condition that tends to cause a high degree of patient distress, IPT has gained visibility over the past several years due to the use of surgery to treat prostate cancer, as well as the proliferation of men’s continence products available to the lay public. Read more.
Source: PRNewswire, May 3, 2019
The UK’s only charity dedicated to bowel and bladder health in children and teenagers in the UK – based in Bristol – today (May 1) marks its 30th anniversary. ERIC has been providing valuable support and advice to parents and children struggling with incontinence, a condition that continues to be heavily stigmatised, for more than three decades and has commemorated its big birthday by making the help it provides even more accessible. In the UK an estimated 900,000, or 1 in 12, 5-19 year olds suffer from bowel and bladder conditions – including bedwetting, daytime wetting, constipation and soiling. Read more.
Source: BristolLive, May 1, 2019
TARIS Bio™, a biopharmaceutical company developing transformational therapies to treat people with debilitating urological disorders, announced today the initiation of a new clinical investigation of TAR-302 for the treatment of overactive bladder (OAB). As a new follow-on arm of the company’s previously concluded Phase 1b trial, the study is designed to investigate the safety, tolerability, and preliminary efficacy of a single 12-week dose of the system, doubling the previous treatment experience and representing a duration that better meets the real-world needs of patients with this serious and chronic disease. Read more.
Source: Yahoo! Finance, May 1, 2019
The American Urological Association (AUA) announced that it has updated its guideline for the diagnosis and treatment of non-neurogenic overactive bladder (OAB) in adult patients. As a result of a 2018 systematic review of recently published studies, AUA modified guideline statement 12 to say clinicians may consider combination therapy with an antimuscarinic agent and beta3-andrenoceptor agonist for patients who are refractory to monotherapy with either of those medications. Read more.
Source: Renal & Urology News, April 25, 2019